MARKET

NVS

NVS

Novartis
NYSE
110.41
+0.48
+0.43%
Opening 15:04 07/26 EDT
OPEN
110.04
PREV CLOSE
109.93
HIGH
110.66
LOW
109.67
VOLUME
570.06K
TURNOVER
0
52 WEEK HIGH
112.48
52 WEEK LOW
88.83
MARKET CAP
223.52B
P/E (TTM)
14.10
1D
5D
1M
3M
1Y
5Y
1D
Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Seeking Alpha · 10h ago
Aristotle International Equity ADR Q2 2024 Commentary
Seeking Alpha · 12h ago
Health Rounds: Researchers discover key to the placebo effect in the brain
Health Rounds: Researchers discover key to the placebo effect in the brain. Existing drugs might curb breast cancer tumors from growing and colon cancer from spreading to the liver. Researchers discover how colorectal cancer cells manage to attach themselves so effectively to liver cells. Scientists find a key piece of a puzzle to explain the placebo effect.
Reuters · 1d ago
Novartis to collaborate with Dren Bio on bispecific antibody therapies
Novartis to collaborate with Dren Bio on bispecific antibody therapies for the treatment of cancer. The company will receive $150M upfront from Novartis and up to $2.85B in milestone payments. Dren bio will receive a $25M equity investment in the company.
Seeking Alpha · 2d ago
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
NASDAQ · 2d ago
Dren Bio Announces Strategic Collaboration with Novartis To Develop Novel Targeted Myeloid Engagers For Cancer; Dren Bio To Receive Total Upfront Consideration Of $150M And Is Eligible To Receive Milestone Payments And Tiered Royalties
Dren Bio to receive total upfront consideration of $150 million. Collaboration with Novartis to advance innovative therapies for cancer. Dren's targeted cell depletion platform will be used to develop antibodies for cancer patients. The collaboration will focus on the discovery and development of therapeutic bispecific antibodies.
Benzinga · 2d ago
FOCUS-Pharma aims to deliver personalized cancer therapies more quickly
Pharma firms working to cut manufacturing turnaround time by as much as half in personalized cancer therapies. These treatments are used for the sickest patients for whom standard treatments have failed. The CAR-T therapies can extend lives of patients with aggressive cancers. Improvements in manufacturing time could be a competitive edge for companies.
Reuters · 2d ago
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Seeking Alpha · 3d ago
More
About NVS
Novartis AG is a Switzerland-based pharmaceutical company. The Company develops, manufactures, and markets branded and generic prescription drugs, active pharmaceutical ingredients (APIs), biosimilars and ophthalmic products. The Company uses science and digital technologies for treatments in the disease areas of immunology, dermatology, cancer, ophthalmology, neuroscience, respiratory, cardiovascular, renal and metabolism. The business activities of the Company are divided into two segments: Innovative Medicines, which includes innovative patent-protected prescription medicines for blood pressure, cancer and other ailments, and Sandoz, which includes generic pharmaceuticals and biosimilars.

Webull offers Novartis AG (ADR) stock information, including NYSE: NVS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVS stock methods without spending real money on the virtual paper trading platform.